MagForce AG: MagForce publishes 2013 Interim Report

             MagForce AG: MagForce publishes 2013 Interim Report

MagForce AG / MagForce publishes 2013 Interim Report . Ad hoc announcement
according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The
issuer is solely responsible for the content of this announcement.

  *Capital increase of €33.5 million successfully completed
  *New glioblastoma study approved by BfArM
  *Ben J. Lipps new Chairman of the Management Board from September 1, 2013
  *Operating expenses significantly reduced thanks to implementation package,
    net loss for the period down 36% to €2.3 million
  *Forecast for 2013 confirmed, roll-out plan will lead to increased net loss

Berlin, September 30, 2013 - MagForce AG (Frankfurt, XETRA:MF6), a leading
medical device company in the field of nanomedicine with a focus on oncology,
today published its figures for the first half of 2013, which ended on June
30, 2013.

Chairman of the Management Board Ben J. Lipps commented: "The key event in the
first half of 2013 was the successful capital increase in March of this year,
which enabled the new glioblastoma study to go ahead. This was approved by the
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) in April. Based on
current developments, we are reiterating our outlook for full-year 2013 as
published in the 2012 Annual Report. Given our roll-out plan, we expect the
net loss from operating activities to be higher than in 2012, largely due to
the start of the new clinical glioblastoma study and to preparations for
market entry in other countries. By the end of the year, a total of three
NanoActivators will have been installed and commissioned for the new study."

The Company recorded a net loss of €2.3 million for the reporting period
(-36%, previous year: €3.4million). This improvement is largely due to the
restructuring measures implemented and the strategic repositioning of the
Company. Operating expenses were reduced by 48% to €1.0 million. The main
reasons for this were the writedowns of long-term financial assets made in the
previous year, the discontinuation of the former research projects, and
reduced staff costs as a result of staff restructuring measures.

In the first half of the year, the Company successfully completed its
previously announced capital increase against cash and noncash contributions
with preemptive rights for shareholders in the total amount of approximately
€33.5 million. The new shares were subscribed in return for cash payments and
noncash contributions, and shareholder loans of €15.9 million were converted
into equity. This left MagForce debt-free and with €17.5 million in cash at
that time.

In June, the  Supervisory Board  of MagForce AG  appointed Dr.  Ben J.  Lipps, 
former CEO of Fresenius Medical Care, as Chairman of the Management Board  and 
Chief Executive Officer of the Company effective September 1, 2013. Dr.  Lipps 
has  represented  the  Company  since  that  date  together  with  his  fellow 
Management Board  members  Prof.  Hoda  Tawfik  (CMO/COO)  and  Christian  von 
Volkmann (CFO), who have remained in their respective positions.

About MagForce AG

MagForce AG is a leading medical device company in the field of nanomedicine
in oncology, listed in the entry standard (MF6). The Company's proprietary,
NanoTherm^® therapy, enables the targeted treatment of solid tumors through
the intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm^®, NanoPlan^®, and NanoActivator(TM) are components
of the therapy and have received EU-wide regulatory approval as medical
devices for the treatment of brain tumors. MagForce, NanoTherm^®, NanoPlan^®,
and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For
more information, please visit


This release may contain forward-looking statements and information which  may 
be  identified  by  formulations  using  terms  such  as  "expects",   "aims", 
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will".
Such forward-looking  statements are  based on  our current  expectations  and 
certain  assumptions,  which  may  be  subject  to  a  variety  of  risks  and 
uncertainties. The results actually achieved by MagForce AG may  substantially 
differ  from  these  forward-looking   statements.  MagForce  AG  assumes   no 
obligation to update these  forward-looking statements or  to correct them  in 
case of developments, which differ from those, anticipated.

MagForce_Press Release_September 30, 2013


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MagForce AG via Thomson Reuters ONE

--- End of Message ---

MagForce AG
Max-Dohrn-Str. 8 Berlin Germany

Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Entry Standard in Frankfurter Wertpapierbörse,
XETRA in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.